Newsletter · · Ashutosh Agarwal

RNDC Bankruptcy Signals a Broken Alcohol Market as Zero Proof Drinks Surge - Beverage Alcohol & Nicotine - Week of August 26, 2026

Beverage Alcohol & Nicotine for the week of August 26, 2026. Podcast synthesis on the bankruptcy of RNDC, one of the two dominant US alcohol distributors, what it says about a genuine demand reset, and how non-alcoholic canned cocktails (growing roughly 75% a year), non-alcoholic wine and THC seltzers are taking the shelf space back.

Beverage Alcohol & Nicotine

Week of August 26, 2026: RNDC Bankruptcy Signals a Broken Alcohol Market as Zero Proof Drinks Surge

There is a difference between a soft quarter and a broken market, and this week we got a sign it may be the latter. The clearest read on the state of drinking didn't come from an earnings call or a Diageo strategy day, it came, almost in passing, from the founder of a non-alcoholic cocktail brand describing how one of the two biggest alcohol distributors in America collapsed underneath her, forcing a scramble to keep her cans on shelves. When the plumbing of the alcohol industry starts failing, that tells you something the volume charts have been hinting at for two years: people are simply drinking less, and the machine built to move all that liquid is now too big for the job. Meanwhile the "better-for-you" side kept compounding, non-alcoholic drinks are spreading from beer into wine and canned cocktails, THC seltzers keep grabbing traditional beer shelf space, and the weight-loss-drug story got more interesting for both booze and cigarettes.

TL;DR

  • One of the two largest US alcohol distributors, RNDC, has filed for bankruptcy, described by a drinks-industry operator as "the behemoth, like the Goliath," a structural crack that goes well beyond any single brand and confirms how far alcohol volumes have fallen. Non-alcoholic canned cocktails, by contrast, are growing about 75% a year.
  • The non-alcoholic wave is no longer just beer. This week alone brought a fast-scaling non-alc cocktail brand (200,000+ cases, aiming to nearly double), a new non-alcoholic wine brand, and a debate among beer insiders over whether the category has too many me-too products. The moderation story keeps hardening.
  • THC drinks keep colonizing alcohol's shelves, one hemp-beverage brand is now doing 100,000+ cases across 20 to 21 states through beer distributors and into Target, while the one genuinely federal risk (a hemp ban) threatens the supply chain, not the demand.

What's new

The single biggest tell of the week: a top-two alcohol distributor went bankrupt, and we heard it from an operator, not a headline. The most useful hour on any podcast this week was Beernet Radio, "Ep. 347 Lara Taylor of Mingle" (Aug 22, 2026), an interview with Lara Taylor, founder of the non-alcoholic brand Mingle. Talking about the health of the drinks business, she named the elephant directly: "seeing good people lose their jobs in a company like RNDC, who's the behemoth, like the Goliath, you know, filed for bankruptcy is really, it's not good for anybody." RNDC, Republic National Distributing Company, is one of the two dominant middlemen in the American three-tier system (producers sell to distributors, who sell to retailers). A distributor of that scale failing is not a brand problem or a bad-weather problem; it is the middle of the industry buckling because there is less liquid to move. Taylor's own read: "Americans are choosing to drink less across all demographics. Millennials are moderating because they're not processing alcohol like they used to... And Gen Z... have started their teenage years and early 20s thinking, I want to know what's going into my body." For anyone modeling the big alcohol names, the RNDC collapse is the hard evidence behind the soft depletion numbers, and a warning that route-to-market disruption could bite shipments in the back half of the year even for healthy brands, who had to scramble mid-stream to new distributors like Reyes and Breakthru.

The other side of that coin is exploding: non-alcoholic canned cocktails are growing roughly 75% a year, and a scrappy brand just showed how big it can get. Same interview. Taylor built Mingle over nine years, she quit drinking eleven years ago and started the brand because "there wasn't anything at those work occasions," and it now sells through Total Wine, Publix, Whole Foods, Walmart and Target. The stat that frames the category: "the story is obviously alcohol sales are going down except for RTDs. That's the one bright spot in the industry... adult non-alcoholic is taking off. And non-alcoholic beer is the biggest part of the category. But RTDs in non-alcoholic have the highest percentage of growth. I think it's 75% year-over-year growth." ("RTD" means ready-to-drink, a pre-mixed cocktail in a can.) Mingle sold more than 200,000 cases last year and Taylor said the plan for next year is "to almost double sales." Her newer functional line, Mingle Mood, launched last October and is "adding the second most dollars year to date" among brand-new RTDs in NielsenIQ data, and, tellingly, it skews Gen Z and gender-neutral rather than her original millennial-female base. When the fastest-growing corner of the entire drinks aisle is the zero-alcohol version, that is the moderation thesis stated from the cash register.

"Americans are choosing to drink less across all demographics." Lara Taylor, founder of Mingle, on Beernet Radio

THC drinks are quietly building a real distribution business inside alcohol, and the only true federal risk is to supply, not demand. On High Spirits: The Cannabis Business Podcast, "#149 - Building a Hemp Beverage Empire Inside Alcohol: Jason Dayton of Trail Magic" (Aug 19, 2026), Dayton, who also runs the national cider brand Crispin, gave the clearest operator picture yet of the category's scale. Trail Magic "will exceed a hundred thousand cases again this year," is "in 20, 21 States through traditional three tier, mostly beer wholesalers," and has pushed into Target in Texas, Florida and Illinois. In other words, THC seltzer is being sold on the exact same trucks and shelves as beer. The nuance that matters for investors is regulatory: Dayton walked through the risk that a federal hemp ban would reclassify these drinks as marijuana, which wouldn't kill the licenses in states like Minnesota but would choke the raw material, "if we lose the ability to have interstate commerce for hemp and distillate, that becomes a problem for supporting a really robust beverage market." The read for anyone watching alcohol's flat-to-down volumes: THC beverages are a genuine new occasion competing for the drinking dollar, they travel through the same distributors who are already under strain, and the swing factor is a Washington supply-chain decision, not consumer appetite.

Celsius showed what "growth by acquisition" looks like when the core brand cracks. On Telltales, "Weekend Update - W2634" (Aug 23, 2026), an AI-generated markets show, so treat this as analysis of the print rather than operator commentary, the hosts walked through Celsius's quarter: second-quarter revenue of $818 million, up 11% year over year, but "every dollar of that growth is Alani Nu, which did $364 million and grew 21%. The Celsius brand itself, the thing the company is named after, declined about 12%." The company also lost its president and COO, former PepsiCo executive Eric Hansen, and installed a new chief commercial officer and a new chief business transformation officer. The point for the wider functional-drinks theme: even the poster child of the energy-and-function boom is now leaning on an acquired brand while its namesake shrinks, a reminder that "functional" is a crowded, fashion-driven shelf where single-brand momentum can reverse fast. It rhymes with the caution a private-equity veteran gave last week, that for every functional-beverage winner there are a hundred that quietly disappear.

The debate

The central question of this newsletter is whether the drop in drinking is a permanent generational shift or a cyclical dip that reverses. This week the evidence leaned hard toward "structural."

Bull (the moderation is structural), and this week it got its most tangible proof point yet. You do not get a top-two distributor filing for bankruptcy in a cyclical soft patch; you get it when the underlying demand base has genuinely reset and the industry's fixed costs no longer fit the volume. Taylor's framing, decline "across all demographics," millennials moderating, Gen Z intentional about "what enters their bodies," is now being confirmed by the industry's own infrastructure failing. And the substitutes are multiplying across every format at once: non-alc beer (the biggest slice), non-alc canned cocktails (the fastest, roughly 75% growth), and now non-alc wine. On Next In Time, "Episode 187: Reinventing Non-Alcoholic Wine | Antonino Li Brizzi, Founder of CLINQ ZERO" (Aug 22, 2026), the founder put it plainly: "Wine industry, wine category is declining. What is growing is non-alcoholic. We saw in beer, we saw in spirits and distillates. Now you got the mocktails out there." His key framing is that not drinking has stopped being an identity ("I'm sober") and become a situational choice, "there is an occasion where alcohol does not fit for whatever reason. People don't have to explain anymore." When the reason to skip a drink no longer needs a justification, the addressable market for zero-proof stops being "sober people" and becomes "everyone, sometimes."

Bear (the dip is cyclical or overstated), carried this week by a note of internal caution rather than by the alcohol majors. The closest thing to a bear voice came from within the moderation camp itself. On Brewbound, "Do We Need Another NA Version of a Legacy Beer Brand?" (Aug 19, 2026), host Justin Kendall pushed back on the idea that every beer now needs a zero-proof twin, singling out Leinenkugel's non-alcoholic summer shandy: "not everything has to be a non-alcoholic beer... I feel like a lot of folks are grasping right now. And we are fighting over a very small piece of the puzzle." His standard is data, not vibes, he'll believe a launch when a brewer can show, as Lawson's did, that roughly 30% of its existing drinkers already buy non-alc. That is a healthy warning that the non-alc shelf is starting to fill with me-too products chasing a still-small (if fast-growing) base, and that the winners will be the brands with real consumer pull, not the ones bolting "0.0" onto a legacy label. Worth noting what the bear case did not have this week: no operator or analyst arguing that overall drinking is about to reaccelerate, and no premiumization-offsets-volume rebuttal.

The GLP-1 wrinkle cuts both ways, and this week the nuance sharpened. The popular version of the story is that weight-loss drugs are quietly killing alcohol demand, and there was fresh clinician support for it. On NeurologyLive Mind Moments, "Exploring the Emerging Role of GLP-1 Therapies in Neurology" (Aug 21, 2026), Dr. Rouhani said patients volunteer the effect unprompted: "I didn't expect to drink less alcohol, but I immediately started to have less craving for alcohol... GLP-1 agonists directly affect the reward pathways of our brain. So there's a very interesting connection there, and I think we can use it for smoking cessation, alcoholism." That is a rare data point that hits both halves of this newsletter, the same biology that dents drinking could also dent smoking. And on Office Hours with David Meltzer, "#917 | Artificial Intelligence, Psychology & the Future of Health" (Aug 19, 2026), a nurse practitioner was blunter still: "I take people off alcohol, stop people from smoking using these medications."

But the counter-nuance is important, and it came from an actual metabolic-health clinic. On The Plus SideZ, "GLP-1s, Bariatric Surgery & the Uncomfortable Truth About Eating Disorders" (Aug 19, 2026), the clinician warned that GLP-1s do not reliably erase the urge to drink, "the desire for alcohol does go away, though. I think that is conflictual and it's not a hundred percent going to just completely make us stop," and that a meaningful subset of patients actually swap food for booze under stress: "we see high rates of substance use disorder, particularly with alcohol." The investable takeaway: GLP-1s are a genuine, growing headwind to alcohol volumes at the population level, but the effect is messier and more individual than the clean "Ozempic kills drinking" narrative, which argues against sizing that headwind too aggressively in a model just yet.

The names in play

This was a thematic week more than a stock-picker's week, but a few public names sit directly under the read.

Celsius (CELH) is the one clean, dated data point: an 11% revenue quarter that is entirely acquired growth (Alani Nu +21% to $364M) masking a 12% decline in the core brand, plus a C-suite reshuffle. Bull: management is diversifying away from single-brand risk and Alani Nu is working. Bear: you don't rebuild three C-suite seats and lean on an acquisition when the flagship is healthy. Next catalyst: whether the new commercial leadership can stabilize the Celsius trademark itself, not just the portfolio.

Boston Beer (SAM) made a cameo on Brewbound via a unionization push at its Sam Adams Jamaica Plain taproom, small in isolation (union headcount is a sliver of the roughly 2,700-person base per its February 10-K), but a reminder that craft's cost pressures are rising just as beer volumes flatten. For the tobacco majors, Philip Morris (PM), Altria (MO), BAT (BTI), the week produced no operator or analyst commentary on Zyn volumes, pouch capacity, heated-tobacco pricing or the smoke-free profit mix, so the only nicotine signal available was cultural, and it's a double-edged one (more below).

Read-throughs

Distributors: the middle tier isn't just consolidating, it's failing. The RNDC bankruptcy is the headline read, but the structural rot underneath it was described independently on Business of Drinks, "130: How Arette Built a 100K-Case Tequila Brand From the Bar Out With Eduardo Orendain" (Aug 19, 2026). Orendain laid out the squeeze: "there were more distributors 30 years ago than there are today," while the number of brands "has grown tremendously," so "the math is not working." A portfolio might now carry "40 tequilas" where it once carried one or two, making it nearly impossible for a small brand to get attention without paying for it. He also noted his own distributor got swallowed, "the only really big distributor that we have is Breakthrough in California... because they bought our previous distributor, Wine Warehouse." Put RNDC's collapse next to that consolidation and the picture is a distribution layer being crushed from both sides: fewer, bigger players, more brands fighting for shelf, and shrinking total volume to carry. For producers, route-to-market risk just became a top-of-model concern; for the surviving big distributors (Reyes, Breakthru and the like), it's a chance to absorb share, including, potentially, the high-margin new THC-beverage line.

Non-alcoholic and functional: the category is broadening faster than it's deepening. Between Mingle (canned cocktails), CLINQ ZERO (wine) and the Brewbound debate (beer), the zero-proof shelf now spans every format, but Brewbound's skepticism and Celsius's core-brand stumble are the same warning in two places: proliferation is outrunning proven demand in the newer sub-categories, and the winners will be brands with real consumer pull, not label extensions. One concrete channel note from Taylor: convenience stores (Wawa, and by extension the c-store majors) are not yet ready for non-alc RTDs because "that shelf space is even more precious," she thinks it's "a year or two" away. So the c-store nicotine-and-alcohol cash cow hasn't been invaded by zero-proof yet, but it's on the map.

Cannabis and THC: a distribution asset, not just a threat. Trail Magic's 100,000-case, 20-state footprint through beer wholesalers shows THC beverages are now a real line item moving through alcohol's own trucks. For beer distributors staring at declining core volumes, hemp drinks are looking less like a competitor and more like a growth SKU to carry, provided Washington doesn't sever the interstate hemp supply chain.

Nicotine: the only signal was consumer-cultural, and it's worth flagging as a demand tell. On Travis Makes Money, "Make Money... With Nicotine? Does It Actually Make You More Productive?" (Aug 20, 2026), the hosts (self-described sales-and-hustle types, so pure anecdote, not data) described how entrenched pouches have become among young men: "every guy that I know that zins, zins every single day," with one host joking "if I had to make up a stat, I would say like 80% of guys zin," and another calling nicotine "any nootropic" and "the new cocaine... just a little bit better for you." Read it as a crude but real signal that pouch demand among young men remains culturally sticky, bullish for total nicotine volumes and the reduced-risk transition the majors are banking on. The offsetting risk sits in the GLP-1 discussion above: if weight-loss drugs really do blunt nicotine cravings via the brain's reward pathways, the same pharmacology denting alcohol could eventually chip at pouches too. Neither force showed up in an earnings number this week, but both are worth watching into the next round of tobacco prints.

What changed

  • The alcohol story escalated from "volumes are soft" to "the distribution system is breaking." Last week the debate was about Diageo's turnaround and who gets to distribute THC drinks. This week a top-two distributor, RNDC, filed for bankruptcy, a structural event that reframes soft depletions as a genuine demand reset, and puts route-to-market risk squarely on the table for the back half of the year.
  • Non-alcoholic went from a beer story to an everything story. In a single week the zero-proof theme showed up in canned cocktails (growing roughly 75%), wine (a new brand), and a beer-insider debate about over-proliferation, a sign the category is maturing and starting to sort winners from me-too launches.
  • The nicotine read stayed anecdotal. The tobacco majors produced no operator commentary this week; the available signals were cultural (pouch stickiness among young men) and pharmacological (GLP-1s possibly aiding smoking cessation). The reduced-risk thesis is running on demand anecdotes rather than fresh margin data.